Related Experiment Video

Updated: Jan 4, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.4K

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

Siyang Yan1,2, Niels Vandewalle1, Nathan De Beule1

  • 1Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, 1090 Brussel, Belgium.

Cancers
|November 8, 2019
PubMed

Insights

AXL receptor tyrosine kinase signaling is crucial in cancer, particularly hematological malignancies. This review highlights AXL

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • AXL receptor tyrosine kinase is part of the TAM family, interacting with GAS6.
  • The GAS6/TAM pathway influences cell processes, immunity, and hemostasis.
  • AXL overexpression in cancer correlates with poor prognosis, proliferation, and metastasis.

Purpose of the Study:

  • To review AXL's function in various cell types.
  • To examine AXL's role in hematological cancers, focusing on multiple myeloma dormancy.
  • To update on AXL inhibitors in clinical development.

Main Methods:

  • Literature review of AXL's role in cell biology and hematological malignancies.
  • Analysis of preclinical and clinical data on AXL inhibitors.
  • Synthesis of current research on AXL in multiple myeloma dormancy.

Main Results:

  • AXL's diverse expression and function in hematological malignancies and their microenvironments.
  • Significant research on AXL inhibitors in acute myeloid leukemia.
  • Emerging evidence for AXL's role in lymphoid leukemia, lymphoma, and multiple myeloma.

Conclusions:

  • AXL is a significant factor in hematological cancers, including multiple myeloma dormancy.
  • Targeting AXL presents a promising therapeutic strategy.
  • Further research and clinical evaluation of AXL inhibitors are warranted.
Keywords:
AXLhematological cancersprognostic valueselective inhibitors

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

585
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K